Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000756810 | Endometrium | AEH | aging | 59/2100 | 339/18723 | 4.00e-04 | 4.28e-03 | 59 |
GO:004328010 | Endometrium | AEH | positive regulation of cysteine-type endopeptidase activity involved in apoptotic process | 28/2100 | 129/18723 | 4.33e-04 | 4.58e-03 | 28 |
GO:00719008 | Endometrium | AEH | regulation of protein serine/threonine kinase activity | 61/2100 | 359/18723 | 6.11e-04 | 5.98e-03 | 61 |
GO:003647315 | Endometrium | AEH | cell death in response to oxidative stress | 22/2100 | 95/18723 | 6.87e-04 | 6.62e-03 | 22 |
GO:200105610 | Endometrium | AEH | positive regulation of cysteine-type endopeptidase activity | 30/2100 | 148/18723 | 9.19e-04 | 8.39e-03 | 30 |
GO:00486613 | Endometrium | AEH | positive regulation of smooth muscle cell proliferation | 23/2100 | 104/18723 | 1.03e-03 | 9.15e-03 | 23 |
GO:00092679 | Endometrium | AEH | cellular response to starvation | 31/2100 | 156/18723 | 1.08e-03 | 9.46e-03 | 31 |
GO:00719026 | Endometrium | AEH | positive regulation of protein serine/threonine kinase activity | 37/2100 | 200/18723 | 1.50e-03 | 1.24e-02 | 37 |
GO:007135610 | Endometrium | AEH | cellular response to tumor necrosis factor | 41/2100 | 229/18723 | 1.66e-03 | 1.36e-02 | 41 |
GO:00316699 | Endometrium | AEH | cellular response to nutrient levels | 39/2100 | 215/18723 | 1.66e-03 | 1.36e-02 | 39 |
GO:19007452 | Endometrium | AEH | positive regulation of p38MAPK cascade | 10/2100 | 32/18723 | 1.94e-03 | 1.52e-02 | 10 |
GO:003461210 | Endometrium | AEH | response to tumor necrosis factor | 44/2100 | 253/18723 | 2.08e-03 | 1.61e-02 | 44 |
GO:003166810 | Endometrium | AEH | cellular response to extracellular stimulus | 43/2100 | 246/18723 | 2.10e-03 | 1.63e-02 | 43 |
GO:00425949 | Endometrium | AEH | response to starvation | 36/2100 | 197/18723 | 2.15e-03 | 1.65e-02 | 36 |
GO:00328743 | Endometrium | AEH | positive regulation of stress-activated MAPK cascade | 25/2100 | 126/18723 | 3.18e-03 | 2.24e-02 | 25 |
GO:19040195 | Endometrium | AEH | epithelial cell apoptotic process | 24/2100 | 121/18723 | 3.81e-03 | 2.60e-02 | 24 |
GO:00703044 | Endometrium | AEH | positive regulation of stress-activated protein kinase signaling cascade | 25/2100 | 128/18723 | 3.95e-03 | 2.65e-02 | 25 |
GO:1904705 | Endometrium | AEH | regulation of vascular associated smooth muscle cell proliferation | 19/2100 | 90/18723 | 4.69e-03 | 2.99e-02 | 19 |
GO:1990874 | Endometrium | AEH | vascular associated smooth muscle cell proliferation | 19/2100 | 91/18723 | 5.32e-03 | 3.32e-02 | 19 |
GO:00703015 | Endometrium | AEH | cellular response to hydrogen peroxide | 20/2100 | 98/18723 | 5.64e-03 | 3.46e-02 | 20 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520820 | Cervix | CC | Chemical carcinogenesis - reactive oxygen species | 92/1267 | 223/8465 | 4.71e-22 | 5.09e-20 | 3.01e-20 | 92 |
hsa0501220 | Cervix | CC | Parkinson disease | 102/1267 | 266/8465 | 1.81e-21 | 1.47e-19 | 8.66e-20 | 102 |
hsa0501018 | Cervix | CC | Alzheimer disease | 113/1267 | 384/8465 | 9.67e-14 | 3.92e-12 | 2.32e-12 | 113 |
hsa0501618 | Cervix | CC | Huntington disease | 94/1267 | 306/8465 | 8.49e-13 | 3.06e-11 | 1.81e-11 | 94 |
hsa0502218 | Cervix | CC | Pathways of neurodegeneration - multiple diseases | 128/1267 | 476/8465 | 2.87e-12 | 9.29e-11 | 5.50e-11 | 128 |
hsa0493218 | Cervix | CC | Non-alcoholic fatty liver disease | 58/1267 | 155/8465 | 3.58e-12 | 1.05e-10 | 6.23e-11 | 58 |
hsa0471420 | Cervix | CC | Thermogenesis | 76/1267 | 232/8465 | 4.29e-12 | 1.16e-10 | 6.85e-11 | 76 |
hsa0501418 | Cervix | CC | Amyotrophic lateral sclerosis | 103/1267 | 364/8465 | 1.79e-11 | 4.47e-10 | 2.64e-10 | 103 |
hsa0541820 | Cervix | CC | Fluid shear stress and atherosclerosis | 50/1267 | 139/8465 | 5.71e-10 | 1.32e-08 | 7.81e-09 | 50 |
hsa0541720 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
hsa0414120 | Cervix | CC | Protein processing in endoplasmic reticulum | 55/1267 | 174/8465 | 1.74e-08 | 2.68e-07 | 1.58e-07 | 55 |
hsa0453020 | Cervix | CC | Tight junction | 49/1267 | 169/8465 | 1.87e-06 | 1.78e-05 | 1.05e-05 | 49 |
hsa0407110 | Cervix | CC | Sphingolipid signaling pathway | 35/1267 | 121/8465 | 5.70e-05 | 3.93e-04 | 2.32e-04 | 35 |
hsa042109 | Cervix | CC | Apoptosis | 36/1267 | 136/8465 | 3.21e-04 | 1.68e-03 | 9.91e-04 | 36 |
hsa0472214 | Cervix | CC | Neurotrophin signaling pathway | 32/1267 | 119/8465 | 5.01e-04 | 2.42e-03 | 1.43e-03 | 32 |
hsa0501716 | Cervix | CC | Spinocerebellar ataxia | 35/1267 | 143/8465 | 1.77e-03 | 7.21e-03 | 4.26e-03 | 35 |
hsa046686 | Cervix | CC | TNF signaling pathway | 28/1267 | 114/8465 | 4.60e-03 | 1.62e-02 | 9.59e-03 | 28 |
hsa040109 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
hsa05208110 | Cervix | CC | Chemical carcinogenesis - reactive oxygen species | 92/1267 | 223/8465 | 4.71e-22 | 5.09e-20 | 3.01e-20 | 92 |
hsa05012110 | Cervix | CC | Parkinson disease | 102/1267 | 266/8465 | 1.81e-21 | 1.47e-19 | 8.66e-20 | 102 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAP3K5 | SNV | Missense_Mutation | rs771379166 | c.3427C>T | p.Arg1143Trp | p.R1143W | Q99683 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MAP3K5 | SNV | Missense_Mutation | | c.1276N>A | p.Glu426Lys | p.E426K | Q99683 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AC-A2B8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | chemo | PD |
MAP3K5 | SNV | Missense_Mutation | | c.3040C>T | p.Arg1014Trp | p.R1014W | Q99683 | protein_coding | deleterious(0.02) | probably_damaging(0.993) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAP3K5 | SNV | Missense_Mutation | | c.702N>C | p.Leu234Phe | p.L234F | Q99683 | protein_coding | tolerated(0.08) | possibly_damaging(0.883) | TCGA-AN-A0AR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAP3K5 | SNV | Missense_Mutation | novel | c.1307N>A | p.Ala436Glu | p.A436E | Q99683 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A0FZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
MAP3K5 | SNV | Missense_Mutation | novel | c.1531N>T | p.Leu511Phe | p.L511F | Q99683 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BH-A0B7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
MAP3K5 | SNV | Missense_Mutation | novel | c.2311N>A | p.Gly771Ser | p.G771S | Q99683 | protein_coding | deleterious(0) | possibly_damaging(0.896) | TCGA-BH-A0BL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
MAP3K5 | SNV | Missense_Mutation | | c.1276G>A | p.Glu426Lys | p.E426K | Q99683 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
MAP3K5 | SNV | Missense_Mutation | novel | c.3817G>A | p.Ala1273Thr | p.A1273T | Q99683 | protein_coding | tolerated(0.79) | benign(0.257) | TCGA-E2-A14R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
MAP3K5 | SNV | Missense_Mutation | novel | c.850C>G | p.Arg284Gly | p.R284G | Q99683 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-GI-A2C9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4217 | MAP3K5 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSCRIPTION FACTOR, ENZYME | | GS-4997 | SELONSERTIB | |
4217 | MAP3K5 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 249565756 | | |
4217 | MAP3K5 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSCRIPTION FACTOR, ENZYME | | GS-4977 | | |
4217 | MAP3K5 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 249565813 | | |
4217 | MAP3K5 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 385612190 | | |
4217 | MAP3K5 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSCRIPTION FACTOR, ENZYME | inhibitor | CHEMBL3545429 | SELONSERTIB | |
4217 | MAP3K5 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSCRIPTION FACTOR, ENZYME | | hydroxyurea | HYDROXYUREA | 23556445 |
4217 | MAP3K5 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 315661125 | SELONSERTIB | |
4217 | MAP3K5 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 404859049 | | |